Manuela Braun
Pharmaceuticals R&D
Berlin, BE 13342, Germany
Berlin, BE 13342, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies by the IQ Consortium.
Journal: Nucleic acid therapeutics
Published: November 08, 2025
Nonclinical toxicity study duration in AAV gene therapy development: Evidence from industry survey supports adequacy of short-term assessments.
Journal: Molecular therapy. Methods & clinical development
Published: August 14, 2025
Current regulatory requirements for assessment of immunogenicity for gene therapy medicinal products.
Journal: Cell reports. Medicine
Published: February 17, 2025
Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirements.
Journal: Molecular therapy. Methods & clinical development
Published: March 18, 2024
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper.
Journal: Molecular therapy. Methods & clinical development
Published: September 12, 2022
Applying context of use to quantitative polymerase chain reaction method validation and analysis: a recommendation from the European Bioanalysis Forum.
Journal: Bioanalysis
Published: October 28, 2021
Recommendations for singlet-based approach in ligand binding assays: an IQ Consortium perspective.
Journal: Bioanalysis
Published: June 20, 2020
Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.
Journal: Cancer research
Published: January 18, 2016
Showing 1-12 of 12
Last Updated: 09/26/2026